Abstract no : 2-1&2-DG-026
Author(s) : Baruah, C.C; Gupta, P.P; Amar Nath, Patnaik, G.K. & Dhawan, B.N.
Address : Division of Pharmacology, Central Drug Research Institute, Lucknow - 226 001,
Source : Ind. Journal of Pharmacology v 29/1 feb 1997.
Title : ANTIALLERGIC ACTIVITY OF PICRORHIZA KURROA
Abstract : Picrorhiza kurroa (KATUKI) is used for the treatment hepatic disorders and allergic conditions in Ayurveda. Picroliv, a standardised fraction isolated from root and rhizome of Picrorhiza kurroa, consisting mainly of iridiod glycosides, picroside 1 and kutkoside was shown to be responsible for its hepatoprotective and immunomodulatory activities. Its anti-passive cutaneous anaphylaxis and mast cell stablising activities were investigated in present study. In order to further establish its antiallergic activity, its effect was studied in experimentally induced anaphylactic reaction (Schultz-Dalle phenomenon) and on Konzett-Roessler preparation. At 12.5 mg/kg p.o., it protected mast cell from degranulation by 5-85%, when induced by comp. 48/80 and antigen respectively, comparable to the standard drug sodium cromoglycate. However, picroliv (10 mg/kg p.o. x 5) could not inhibit Schultz-ale phenomenon in antigen presensitised guinea pig ileum, but in vitro studies with picroliv (1-5 µg/ml) showed inhibition (10.70%) of antigen induced contraction dose dependently. The contraction induced by histamine in the normal guinea pig ileum remained unaffected by Picroliv. Similarly, in the Konzett-Roesseler preparation in normal guinea pig, it failed to affect the bronchoconstriction induced by histamine or acetylcholine indicating the lack of effect of picroliv at the post-synaptic level. In the sensitised guinea pig the bronchoconstriction induced by egg albumin, was effectively blocked by Picroliv. Thus it can be concluded that Picroliv Showed a prominent anti-allergic activity and that the activity could be due to inhibition of phenomenon of sensitisation by immunomodulation
Author(s) : Baruah, C.C; Gupta, P.P; Amar Nath, Patnaik, G.K. & Dhawan, B.N.
Address : Division of Pharmacology, Central Drug Research Institute, Lucknow - 226 001,
Source : Ind. Journal of Pharmacology v 29/1 feb 1997.
Title : ANTIALLERGIC ACTIVITY OF PICRORHIZA KURROA
Abstract : Picrorhiza kurroa (KATUKI) is used for the treatment hepatic disorders and allergic conditions in Ayurveda. Picroliv, a standardised fraction isolated from root and rhizome of Picrorhiza kurroa, consisting mainly of iridiod glycosides, picroside 1 and kutkoside was shown to be responsible for its hepatoprotective and immunomodulatory activities. Its anti-passive cutaneous anaphylaxis and mast cell stablising activities were investigated in present study. In order to further establish its antiallergic activity, its effect was studied in experimentally induced anaphylactic reaction (Schultz-Dalle phenomenon) and on Konzett-Roessler preparation. At 12.5 mg/kg p.o., it protected mast cell from degranulation by 5-85%, when induced by comp. 48/80 and antigen respectively, comparable to the standard drug sodium cromoglycate. However, picroliv (10 mg/kg p.o. x 5) could not inhibit Schultz-ale phenomenon in antigen presensitised guinea pig ileum, but in vitro studies with picroliv (1-5 µg/ml) showed inhibition (10.70%) of antigen induced contraction dose dependently. The contraction induced by histamine in the normal guinea pig ileum remained unaffected by Picroliv. Similarly, in the Konzett-Roesseler preparation in normal guinea pig, it failed to affect the bronchoconstriction induced by histamine or acetylcholine indicating the lack of effect of picroliv at the post-synaptic level. In the sensitised guinea pig the bronchoconstriction induced by egg albumin, was effectively blocked by Picroliv. Thus it can be concluded that Picroliv Showed a prominent anti-allergic activity and that the activity could be due to inhibition of phenomenon of sensitisation by immunomodulation
Comments
Post a Comment